A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
about
Neuropathic pain and psychological morbidity in patients with treated leprosy: a cross-sectional prevalence study in MumbaiPomalidomide therapy for multiple myeloma and myelofibrosis: an update.Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis.Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaThalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myelomaThalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyThe rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyThe Belgian 2010 consensus recommendations for the treatment of multiple myeloma.New immunomodulatory drugs in myeloma.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Novel immunomodulatory compounds in multiple myeloma.Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist.Current strategies for treatment of relapsed/refractory multiple myeloma.Pomalidomide for multiple myeloma.Therapy-related peripheral neuropathy in multiple myeloma patients.Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea.Triplet vs. doublet drug regimens for managing multiple myeloma.Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.Percutaneous vertebroplasty in multiple myeloma: prospective long-term follow-up in 106 consecutive patients.The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma.Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myelomaEffect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other ImmunosuppressivesEvaluating Treatment Strategies for Spinal Lesions in Multiple Myeloma: A Review of the Literature
P2860
Q28477357-C59AA318-7215-4989-96BC-A342F282B41EQ34165935-DFBF1FC5-56D6-4970-AC42-B999A37F831DQ35104606-2D15AE49-AF29-4937-B699-08FC5AC1B927Q35172445-A5CB519E-C7BA-48CF-984E-38858325068BQ35200765-50AB0DE5-60D0-413E-B9F3-ED0C4C3A81B8Q36148528-5C864E24-399E-43B0-BBDA-7D7AB80AA7E6Q36382493-3AA00D42-0919-40EC-9EC1-27E858367674Q36612613-D9F7AA81-79A4-4C81-811A-853F18FCFAF0Q37655019-F8813084-2020-4134-851E-B5066E238A64Q37800884-9F33B798-0747-4AEF-BFFF-8A577BADF6ABQ37843770-1C186755-B48E-48D4-A086-5EC140E2620DQ37851944-2C91CDAA-B6C5-4E6A-AD80-5929166B9787Q38069614-344DDD15-FF4D-4A82-B212-F775F7023B4DQ38111390-33BDE244-9231-415A-826F-07C8BFE2EA3DQ38182683-CE6FCBD0-B03A-4A36-8624-68F5B22C3B5EQ38255265-5CFE6209-F852-44DF-866B-31C8DE097E74Q38268525-D41924E8-61F4-445D-93A6-25D15E86CC1AQ38658649-940B92A7-38BD-4961-B189-23165165990DQ39369772-134FEA78-96B4-4154-A402-30719E172CC0Q39584752-B43534A4-E179-4188-AEE9-3BAF450919C6Q40813914-85504F82-7058-43AB-8CC9-FBEF8401BFDDQ47770089-4659499F-C0FD-4EA4-BB74-818A42169009Q52686509-04A7A97D-B622-4CDB-8077-130B2B843611Q53245450-ED7F7381-D6B4-4B5C-935C-A60D4C8A888BQ55513961-AC7696FC-44FC-42B2-A353-A8073FD79868Q56982314-2C3F9A25-13EF-418A-A52A-999104A52492Q57076619-AFD985EC-CDBD-471E-9908-9F680D3605C3Q58563417-8EF43DDF-E4A3-41AC-9941-007CEDE7F5EF
P2860
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A systematic review of phase I ...... or refractory multiple myeloma
@en
A systematic review of phase I ...... r refractory multiple myeloma.
@nl
type
label
A systematic review of phase I ...... or refractory multiple myeloma
@en
A systematic review of phase I ...... r refractory multiple myeloma.
@nl
prefLabel
A systematic review of phase I ...... or refractory multiple myeloma
@en
A systematic review of phase I ...... r refractory multiple myeloma.
@nl
P2093
P2860
P921
P1476
A systematic review of phase I ...... or refractory multiple myeloma
@en
P2093
Axel Glasmacher
Corinna Hahn-Ast
Florian Hoffmann
Gordon Cook
Kerstin Furkert
Marie von Lilienfeld-Toal
Ralf Bargou
Ralph Naumann
P2860
P304
P356
10.1111/J.1600-0609.2008.01121.X
P5008
P577
2008-07-10T00:00:00Z
2008-10-01T00:00:00Z